Vaccine Adjuvants: Key Tools for Innovative Vaccine Design

被引:52
作者
Riese, Peggy [1 ]
Schulze, Kai [1 ]
Ebensen, Thomas [1 ]
Prochnow, Blair [1 ]
Guzman, Carlos A. [1 ]
机构
[1] Helmholtz Ctr Infect Res, Dept Vaccinol & Appl Microbiol, D-38124 Braunschweig, Germany
关键词
Adjuvants; adjuvant combinations; adjuvant licensing; delivery systems; limitations; regulatory aspects; vaccines; parenteral vaccination; mucosal vaccination; T-CELL RESPONSES; CYCLIC-DI-GMP; HEPATITIS-B-VACCINE; IMMUNOSTIMULATORY PHOSPHOROTHIOATE OLIGONUCLEOTIDE; CPG-CONTAINING OLIGODEOXYNUCLEOTIDES; ACTIVE SPECIFIC IMMUNOTHERAPY; CUTANEOUS DENDRITIC CELLS; HUMORAL IMMUNE-RESPONSES; HEAT-LABILE ENTEROTOXIN; POTENT MUCOSAL ADJUVANT;
D O I
10.2174/15680266113136660183
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Vaccines represent the most efficient tool for preventing diseases caused by infectious pathogens. During the last century significant progress has been made in vaccine development, resulting in the eradication or control of several diseases. However, the emergence of new pathogens and the inadequate protection conferred by some existing vaccines render necessary new vaccination strategies. Newly arising immunization approaches, such as subunit vaccines and mucosal administration, make the use of novel adjuvants essential. However, only a limited number of adjuvants are available on the market. The present review is focused on vaccine adjuvants approved for human vaccines and promising candidates which are currently under development. In this regard, emerging immune stimulators and combinations are discussed, together with their strengths, limitations and regulatory framework.
引用
收藏
页码:2562 / 2580
页数:19
相关论文
共 234 条
  • [1] Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant
    Adams, Sylvia
    O'Neill, David W.
    Nonaka, Daisuke
    Hardin, Elizabeth
    Chiriboga, Luis
    Siu, Kimberly
    Cruz, Crystal M.
    Angiulli, Angelica
    Angiulli, Francesca
    Ritter, Erika
    Holman, Rose Marie
    Shapiro, Richard L.
    Berman, Russell S.
    Berner, Natalie
    Shao, Yongzhao
    Manches, Olivier
    Pan, Linda
    Venhaus, Ralph R.
    Hoffman, Eric W.
    Jungbluth, Achim
    Gnjatic, Sacha
    Old, Lloyd
    Pavlick, Anna C.
    Bhardwaj, Nina
    [J]. JOURNAL OF IMMUNOLOGY, 2008, 181 (01) : 776 - 784
  • [2] Cationic Liposomes Formulated with Synthetic Mycobacterial Cordfactor (CAF01): A Versatile Adjuvant for Vaccines with Different Immunological Requirements
    Agger, Else Marie
    Rosenkrands, Ida
    Hansen, Jon
    Brahimi, Karima
    Vandahl, Brian S.
    Aagaard, Claus
    Werninghaus, Kerstin
    Kirschning, Carsten
    Lang, Roland
    Christensen, Dennis
    Theisen, Michael
    Follmann, Frank
    Andersen, Peter
    [J]. PLOS ONE, 2008, 3 (09):
  • [3] Vaccine adjuvants revisited
    Aguilar, J. C.
    Rodriguez, E. G.
    [J]. VACCINE, 2007, 25 (19) : 3752 - 3762
  • [4] Ahmed N, 2009, EXPERT REV VACCINES, V8, P543, DOI [10.1586/erv.09.26, 10.1586/ERV.09.26]
  • [5] Four year immunogenicity of the RTS,S/AS02A malaria vaccine in Mozambican children during a phase IIb trial
    Aide, Pedro
    Dobano, Carlota
    Sacarlal, Jahit
    Aponte, John J.
    Mandomando, Inacio
    Guinovart, Caterina
    Bassat, Quique
    Renom, Montse
    Puyol, Laura
    Macete, Eusebio
    Herreros, Esperanza
    Leach, Amanda
    Dubois, Marie-Claude
    Demoitie, Marie-Ange
    Lievens, Marc
    Vekemans, Johan
    Loucq, Christian
    Ballou, W. Ripley
    Cohen, Joe
    Alonso, Pedro L.
    [J]. VACCINE, 2011, 29 (35) : 6059 - 6067
  • [6] ALMEIDA JD, 1975, LANCET, V2, P899
  • [7] Adjuvants for human vaccines
    Alving, Carl R.
    Peachman, Kristina K.
    Rao, Mangala
    Reed, Steven G.
    [J]. CURRENT OPINION IN IMMUNOLOGY, 2012, 24 (03) : 310 - 315
  • [8] Design and selection of vaccine adjuvants: animal models and human trials
    Alving, CR
    [J]. VACCINE, 2002, 20 : S56 - S64
  • [9] Andrade Fernanda, 2011, Curr Drug Discov Technol, V8, P157
  • [10] [Anonymous], 2010, VIR TECHN